Nivolumab
- TRADE NAME: Opdivo (Bristol-Myers Squibb)
- INDICATIONS: Metastatic squamous non-small cell lung cancer with progression on or after platinum-based chemotherapy; unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor; advanced renal cell carcinoma with prior anti-angiogenic therapy; Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation and post-transplantation brentuximab vedotin; head and neck cancer; colon cancer; liver cancer
- CLASS: Biologic, Immune checkpoint inhibitor, Monoclonal antibody, Programmed death receptor-1 (PD-1) inhibitor
- HALF-LIFE: 27 days
FDA APPROVAL DATE: 03/04/2015
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:None known
PREGNANCY CATEGORY: N/A
Can cause fetal harm
Please login to see the rest of this drug profile
SKIN.
HAIR.
NAILS.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RENAL.
RESPIRATORY.
OTHER.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of nivolumab in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 01/22/2021
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
